
|Articles|April 1, 2003
Oral Pimecrolimus
Maui, Hawaii - A 12-week dose-finding study evaluating oral pimecrolimus for the treatment of chronic plaque-type psoriasis has yielded encouraging safety and efficacy results, Alice B. Gottlieb, M.D., Ph.D., said at the annual Hawaii Dermatology Seminar, sponsored by the Skin Disease Education Foundation.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
2
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
3
Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases
4
Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine
5











